Jennifer Morris
Psychiatry · Edmond, OKNPI 1588650964
Payments from drug & device makers
Across 1,487 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$6K
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$1K
- plus $12K from 41 others
What the payments were for
- Speaking & faculty fees$4,67518%
- Food & beverage$21,56382%
- Education$2101%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,449 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelsomraSuvorexant | 49 | $20,865 |
| QuviviqDaridorexant Hcl | 32 | $15,966 |
| MounjaroTirzepatide | 11 | $12,038 |
| VyvanseLisdexamfetamine Dimesylate | 25 | $9,429 |
| DayvigoLemborexant | 15 | $4,916 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 21 | $4,313 |
| Lisdexamfetamine Dimesylate | 25 | $4,078 |
| Doxepin Hcl | 33 | $3,445 |
| Armodafinil | 46 | $2,570 |
| Trazodone Hcl | 105 | $1,575 |
| Bupropion XlBupropion Hcl | 41 | $1,466 |
| Clorazepate Dipotassium | 12 | $1,366 |
| Escitalopram Oxalate | 37 | $1,175 |
| Duloxetine Hcl | 31 | $1,033 |
| Lamotrigine | 57 | $1,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckBelsomra | $468 | $20,86549 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $150 | $15,96632 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $99 | $12,37527 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $1,406 | $9,42925 claims |
| Eisai Inc.Dayvigo | $333 | $4,91615 claims |
| Almatica Pharma LLCSertraline Hcl | $22 | $73550 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Edmond
- Dennis HeaneyEdmond$12K
- Shawn KhavariEdmond$11K
- Melanie BarrettEdmond$3K
- Louise ThurmanOklahoma City$6.2M
- Veronique SebastianOklahoma City$3.8M
- Marvin PeytonOklahoma City$3.2M
- Sarah LandTulsa$2.8M
- Robert MortonAda$1.9M
- Willis HollowayOklahoma City$1.4M
- Courtney NixonOklahoma City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.